Abstract
Tuberculosis is the second leading cause of death from infectious diseases. Although antitubercular drugs have been traditionally administered orally, there is a growing interest in delivering drugs via the pulmonary route using nebulisers or dry powder inhalers. Drugs in dry powder inhalers (DPI) are stable and DPI are user-friendly compared to nebulisation which is time consuming, inconvenient and inefficient and requires special equipment. For tuberculosis treatment, drugs should target alveolar macrophages that harbour microorganisms and/or maintain high drug concentration at the infection site in the lung. Drug particles include micro-particles or nanoparticles. Powders can be engineered by micronisation, crystallisation, spray drying, freeze drying and particle coating approaches. The formulation may contain single or combination drugs. This paper will provide an update on current status of TB, its pathogenesis, current treatment strategies, shortcomings of current oral or parenteral delivery strategies, pulmonary delivery devices, advantages of pulmonary delivery of powder formulations, formulation approaches and pharmacokinetic studies of pulmonary delivery of powders for inhalation.
Keywords: Dry powder inhaler, microparticles, powder formulation, pulmonary delivery, spray drying, tuberculosis.
Current Drug Delivery
Title:Inhaled Dry Powder Formulations for Treating Tuberculosis
Volume: 12 Issue: 1
Author(s): Shyamal Das, Ian Tucker and Peter Stewart
Affiliation:
Keywords: Dry powder inhaler, microparticles, powder formulation, pulmonary delivery, spray drying, tuberculosis.
Abstract: Tuberculosis is the second leading cause of death from infectious diseases. Although antitubercular drugs have been traditionally administered orally, there is a growing interest in delivering drugs via the pulmonary route using nebulisers or dry powder inhalers. Drugs in dry powder inhalers (DPI) are stable and DPI are user-friendly compared to nebulisation which is time consuming, inconvenient and inefficient and requires special equipment. For tuberculosis treatment, drugs should target alveolar macrophages that harbour microorganisms and/or maintain high drug concentration at the infection site in the lung. Drug particles include micro-particles or nanoparticles. Powders can be engineered by micronisation, crystallisation, spray drying, freeze drying and particle coating approaches. The formulation may contain single or combination drugs. This paper will provide an update on current status of TB, its pathogenesis, current treatment strategies, shortcomings of current oral or parenteral delivery strategies, pulmonary delivery devices, advantages of pulmonary delivery of powder formulations, formulation approaches and pharmacokinetic studies of pulmonary delivery of powders for inhalation.
Export Options
About this article
Cite this article as:
Das Shyamal, Tucker Ian and Stewart Peter, Inhaled Dry Powder Formulations for Treating Tuberculosis, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140716123050
DOI https://dx.doi.org/10.2174/1567201811666140716123050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interplay of Immunity and Vitamin D: Interactions and Implications with Current IBD Therapy
Current Medicinal Chemistry The Effects of Melatonin on the Oxidative Stress and Duration of Atrial Fibrillation after Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Mucosal Co-Infections and HIV-1 Transmission and Pathogenesis)
Current HIV Research Antibacterial Activity and Structure-activity Relationship Studies of 4- substituted-5-(diphenylmethyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones
Letters in Drug Design & Discovery Alcohol Abuse, Immunosuppression, and Pulmonary Infection
Current Drug Abuse Reviews Synthesis and Anti-onchocercal Activity of Isonicotinoylhydrazones and their Copper(II) and Zinc(II) Complexes
Anti-Infective Agents Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein
Medicinal Chemistry Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals
Current Pharmaceutical Design Evaluation of Various Diagnostic Techniques for the Diagnosis of Pulmonary and Extra Pulmonary Tuberculosis at a Tertiary Care Center in North India
Infectious Disorders - Drug Targets Exploring and Exploiting Gene Networks That Regulate Natural Products Biosynthesis in Actinobacteria
The Natural Products Journal Estimation of Mortality from Vital Registrations in South Africa
Current HIV Research Resistant TB: Newer Drugs and Community Approach
Recent Patents on Anti-Infective Drug Discovery Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases
Current Pharmacogenomics Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery In Vitro Anti-mycobacterial Activity of Three Medicinal Plants of Lamiaceae Family
Recent Patents on Anti-Infective Drug Discovery Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design